Telo Genomics Corp. filed a Form D with the Securities and Exchange Commission on 2026-04-24.
Telo Genomics Corp. filed a Form D notice of an exempt securities offering with the SEC on April 24, 2026. The filing reports $7K sold. Its industry group is Biotechnology. It names John Farlinger (Chairman), Sabine Mai (Director, Promoter), John Price (Executive Officer) (SEC Form D, April 24, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Telo Genomics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Telo Genomics Corp.
Free to see. No signup.
More on the people and the money behind Telo Genomics Corp., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Telo Genomics Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Telo Genomics Corp. raises, hires or launches. No email unless you switch it on.
Watch Telo Genomics Corp. →Get the full cited report on Telo Genomics Corp.
What the filing shows about Telo Genomics Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Telo Genomics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Telo Genomics Corp.'s address as 1060 Quebec Street, Vancouver, A1 V6A 4K8.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Telo Genomics Corp. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Telo Genomics Corp. is a registered filer with the SEC (CIK 1872138) and has filed since 2025-01-06. 2 filings are on record, the latest on 2026-04-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Telo Genomics Corp.'s Form D of 2026-04-24 names John Farlinger, Sabine Mai, John Price and 1 more as its officers, directors or promoters.
Its new offerings report $17K sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $7K, on the same scale — one filing against the whole group's total, so it sits low by construction.
A portion of the net proceeds may be used for general working capital purposes, including for payments to officers and directors in the ordinary course, but proceeds are not earmarked for such payments
On the filing as: Executive Officer, Director.
John Farlinger is named as Chairman on the Form D that Telo Genomics Corp. filed with the SEC on 24 April 2026, one of 4 people that filing names.
Sabine Mai is named as Director and Promoter on the Form D that Telo Genomics Corp. filed with the SEC on 24 April 2026, one of 4 people that filing names.
John Price is named as Executive Officer on the Form D that Telo Genomics Corp. filed with the SEC on 24 April 2026, one of 4 people that filing names.
Ron McGlennen is named as Director on the Form D that Telo Genomics Corp. filed with the SEC on 24 April 2026, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2026-04-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Telo Genomics Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Telo Genomics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Telo Genomics Corp. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Telo Genomics Corp.You get an alert in MentionFox the next time this company shows up.
If you're behind Telo Genomics Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Telo Genomics Corp.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/telo-genomics-corp-form-d-26000001